Chip stocks fall with Nvidia after data center rev disappointment
Investing.com -- Emergent BioSolutions Inc (NYSE:EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication treatment to the U.S. government.
The company secured the modification from the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services. Under the agreement, Emergent will provide additional doses of CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV), which treats complications arising from smallpox vaccination.
This modification exercises an option from ASPR’s existing 10-year contract with Emergent (contract number 75A50119C00037) for the treatment, which is part of the U.S. government’s smallpox preparedness strategy.
"Securing this contract modification for VIGIV treatment underscores Emergent’s ongoing partnership with the U.S. government to support its overall smallpox preparedness strategy," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent.
The company did not disclose the financial terms of the contract modification in its announcement. Emergent BioSolutions specializes in developing and manufacturing medical countermeasures for public health threats through its North American supply chain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.